

# Pushpendra Goswami

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3914135/publications.pdf>

Version: 2024-02-01

11  
papers

77  
citations

1478505

6  
h-index

1474206

9  
g-index

11  
all docs

11  
docs citations

11  
times ranked

49  
citing authors

#	ARTICLE	IF	CITATIONS
1	Haematological malignancy: Are we measuring what is important to patients? A systematic review of quality-of-life instruments. <i>European Journal of Haematology</i> , 2019, 102, 279-311.	2.2	18
2	Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 523-533.	1.4	12
3	Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072095500.	2.5	12
4	Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity. <i>Frontiers in Pharmacology</i> , 2020, 11, 209.	3.5	9
5	Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 1308.	3.5	7
6	Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies. <i>Blood</i> , 2018, 132, 2294-2294.	1.4	6
7	Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation. <i>Blood</i> , 2016, 128, 5985-5985.	1.4	6
8	Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO. <i>Frontiers in Pharmacology</i> , 2020, 11, 571066.	3.5	3
9	Translating the Science of Patient Reported Outcomes into Practice: Meaningfulness of HM-PRO Scores in Patients with Hematological Malignancies. <i>Blood</i> , 2018, 132, 4860-4860.	1.4	3
10	Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO. <i>Blood</i> , 2019, 134, 3484-3484.	1.4	1
11	Impact of AML on Patients' Lives: The Value of HM-PRO Measurements. <i>Blood</i> , 2018, 132, 5900-5900.	1.4	0